4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ensysce Biosciences, Inc. (ENSC) operates in the Biotechnology industry and is headquartered in La Jolla, United States with about 8 employees. Its market capitalization is roughly $4 million. In the fiscal year ended 2025-12-31, ENSC reported $0M in revenue and ($10M) in net income.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States.
Interactive charts & full statements → Open the ENSC valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($10M) | ($7M) | ($11M) | ($24M) | — |
| Net Income | ($10M) | ($8M) | ($11M) | ($24M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($4M) | ($3M) | ($4M) | ($2M) | ($2M) | — |
| Net Income | ($4M) | ($3M) | ($4M) | ($2M) | ($2M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $8M | $6M | $3M | $6M | — |
| Total Liabilities | $5M | $2M | $3M | $10M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ENSC viewer.
About TickerBase · Data methodology & sources